9 AI News and Ratings on Investors’ Radar

5. Veracyte, Inc. (NASDAQ:VCYT)

Number of Hedge Fund Holders: 30

Veracyte, Inc. (NASDAQ:VCYT) provides genomic diagnostic tests for various cancers, including thyroid, prostate, bladder, breast, and lung.

Veracyte shared new findings at EAU25 (March 21-24), demonstrating that its whole-genome sequencing (WGS)-based MRD testing platform integrates AI and detects cancer recurrence in muscle-invasive bladder cancer (MIBC) patients with higher accuracy than ddPCR-based blood testing and earlier than standard imaging. Data from the TOMBOLA trial showed that Veracyte’s test matched ddPCR in negative predictive value but had greater specificity and detected recurrence an average of 93 days earlier than imaging. The platform combines WGS and AI to analyze tumor-specific mutations, using minimal blood samples for faster results and continuous monitoring of cancer progression. Veracyte aims to introduce its first MRD test for MIBC in 2026, with plans to expand to other cancers.